TruthArchive.ai - Related Video Feed

A recent paper suggests that COVID vaccines may meet the multi-hit hypothesis for cancer. According to the paper, the vaccines affect the p53 and BRCA tumor suppressor systems, impair DNA repair, and contain DNA fragments with cancer-promoting properties. The presence of SV40, a known cancer promoter, in the vaccines further supports this hypothesis. While it is important to note that this applies to some individuals, it suggests a potential link between the vaccines and cancer development.

The injections target the immune system, causing damage and acting as multi-warheads designed to injure or kill people immediately, intermittently, or in the long run, potentially causing cancer. Turbo cancer occurs in people who already had cancer. The injections destroy the immune system, allowing existing cancers to progress rapidly. It takes a long time for cancer to progress and do damage because the immune system eliminates many aneuploidy cells. Cancers cannot develop quickly unless in cell culture with SV40 and no immune system. The speaker suspected, and it turned out to be true, that the injections were destroying the immune system, revealing undiagnosed cancers. Most people getting cancer suddenly and dying likely already had it. Severely disabling the immune system allows these pre-existing conditions to proliferate.

Vitamin C is distinct from traditional chemotherapy, which can harm both cancerous and healthy tissues. Instead, vitamin C selectively targets cancer cells while preserving normal cells. This unique property can help maintain the health of normal tissues, enhancing the effectiveness of other cancer treatments. Additionally, vitamin C may boost the immune system, enabling it to more effectively combat cancer.

I wrote an article about IgG 4, an antibody produced after 2 COVID vaccines that may affect cancer surveillance. Research into this phenomenon faces criticism, but it's crucial to understand the mechanism behind cancer development post-vaccination. Recent findings reveal DNA contamination in vaccines, including the oncogenic simian virus 40 promoter, potentially leading to cancer. This discovery sheds light on a new possible mechanism for vaccine-related cancers.

VAERS, the Vaccine Adverse Event Reporting System, collects data on vaccine-related adverse events. Analysis shows that in 2021, 98% of cancer-related reports were linked to COVID vaccines, significantly higher than other vaccines. A comparison with the flu vaccine revealed virtually no cancer cases associated with it, highlighting a stark contrast. Research indicates that PD L1, a receptor produced by cancer and immune cells, may contribute to this issue. Elevated PD L1 levels were observed two days after vaccination, suggesting an activated immune system may suppress responses to both COVID and cancer. This nonspecific immunosuppressive effect raises concerns about the potential for increased cancer risk following vaccination.

In major metropolitan areas in the US, getting an appointment at an oncology clinic can take months. The long-term effects of new products like vaccines causing cancer are not immediately observable. Cancer takes time to develop, ranging from 2-3 years for blood cancers to 20-30 years for other types. However, clinicians have observed strange occurrences, such as colon cancer in young individuals without family history. The speaker believes that if the immune system is damaged, it may not be able to recognize or disable cancer cells, leading to their multiplication. COVID vaccines have been found to damage the immune system in some individuals, potentially increasing the risk of cancer in the long term. There have been reports of aggressive cancers appearing relatively soon after vaccination, leading to the term "turbocancers." The connection between cancer occurrence and vaccination is difficult to establish due to weak data. The pandemic lockdowns may have affected cancer diagnoses, but not the aggressive nature of the cancers observed.

The symposium covers the potential safety and threat of “replicating” vaccines, especially LepriCon (leprecon) vaccines, in the context of Covid-19 vaccines and genome‑editing concepts. The speakers present a chain of claims and concerns, some drawing on reports and others presenting theories about how these next‑generation vaccines could behave in humans and populations. Key points and claims presented - Emerging mechanisms and risks: The panel notes that blood vessel inflammation and thrombosis mechanisms are increasingly observed, including in vaccine contexts, with examples from individuals who needed limb amputation and others who developed severe vascular events after vaccination. One case involved a 70‑year‑old man who, after a third dose, developed embolic events necessitating shoulder joint surgery, and another where a 60‑year‑old man developed acute limb ischemia and died; both are presented as suggesting a serious vascular mechanism linked to vaccination, though causal connections are not established. - Replicating/vector vaccines and their concerns:荒川博士 and others discuss LepiCon vaccines as vaccines that replicate inside the body. The concept involves “replicating viral vectors” where the genome can mutate and evolve during replication. The green‑highlighted segment in a slide (the antigen gene) plus a blue/orange segment (replicating gene cassette) is used to describe how LepriCon vaccines are designed to carry viral genes and replicate, with the assertion that replication, mutation, and recombination can occur, potentially generating new variants inside the host. - Differences from conventional vaccines: The discussion contrasts LepriCon vaccines with standard mRNA vaccines. In conventional mRNA vaccines, messenger RNA is delivered and translated into antigen proteins, then degraded; in LepriCon vaccines, replicating RNA/DNA can persist and continue producing antigen, with mutation and recombination possible. The panel emphasizes that LepriCon vaccines use replicating/copying mechanisms and that the genetic material can be copied in ways that differ from natural human biology, potentially creating unpredictable variants. - Central dogma and exceptions: The speakers reference the central dogma (DNA → RNA → protein) but note exceptions in viruses, including RNA viruses that can reverse‑transcribe to DNA (retroviruses) and RNA viruses that replicate RNA directly. They discuss how LepriCon vaccines would rely on replicative processes that do not follow the usual linear flow and why this could complicate predictions about safety and behavior in humans. - Potential for unintended spread and environmental impact: A major concern raised is that self‑replicating vectors could spread beyond the vaccinated individual, via exosomes or other intercellular transport, creating secondary infections or non‑target spread. Exosomes could ferry replicating genetic material, raising fears of new infection chains or “outbreaks” stemming from the vaccine itself, and even suggesting the possibility of vaccination‑induced spread akin to an attenuated or modified pathogen. - Safety signals and immunology concerns: The discussion touches on immune system risks, including immune dysregulation, autoimmune phenomena, and unexpected inflammatory responses. IGG4‑related disease is highlighted as a potential adverse outcome post‑vaccination, with descriptions of glandular and systemic involvement and the idea that high IGG4 levels could have immunosuppressive effects that alter responses to infection or vaccination. The panel notes observed increases in certain immunoglobulin subclasses after multiple LepriCon doses and discusses the possibility of immune tolerance or enhanced immune responses that could be harmful. - Historical and theoretical context: References are made to past epidemics and speculative pandemics caused by misused or dangerous vaccine platforms, drawing on central molecular biology concepts and historical anecdotes about how vaccines can be designed and misused. The discussion frames LepriCon vaccines as a high‑risk platform that could, in theory, generate recombinants, escape mutations, or cause unintended immune and inflammatory consequences. - Clinical and regulatory implications: The speakers call for caution, arguing that more evidence is needed before approving or widespread use of LepriCon vaccines. They emphasize the need for long‑term observation and transparent communication about risks, and criticize the potential for insufficient understanding among healthcare workers and the public. They also urge that any future vaccine development should consider the possibility of genome editing, recombination, and exosome‑mediated spread, and stress the importance of not underestimating possible adverse effects. - Real‑world observations and skepticism about hype: Several speakers underscore that the danger is not merely hypothetical; there are reports of adverse events, including stroke‑like conditions, inflammatory diseases, and immune dysregulation in vaccinated individuals. They stress that the evolution and mutation of replicating vaccines could outpace current surveillance methods, and that “information manipulation” or lack of transparent reporting could mislead the public about risks. - Final reflections and call to action: The concluding messages advocate recognizing the potential failures of messenger RNA vaccines and acknowledging that both conventional and replicating platforms may carry risks. The speakers urge ongoing critical analysis, cautious progression, and robust verification of claims through transparent, independent investigation. They close with thanks to the organizers and a hope that the discussion may contribute to broader public awareness and informed decision‑making. Notable emphasis and unique considerations - The core concern centers on LepriCon vaccines’ replication, mutation, and potential to spread beyond the vaccinated person; exosome transport and genomic/cellular integration are highlighted as mechanisms that could generate new risks not present with non‑replicating vaccines. - The discussion stresses that IGG4 responses could become alarmingly high after certain doses, potentially leading to immunosuppressive effects or autoimmune phenomena, and presents IGG4‑related disease as a potential complication to monitor. - The speakers insist that safety and transparency are paramount, and that misinformation or optimistic narratives about rapid vaccine development could lead to harm if new platforms are adopted without comprehensive evaluation. Overall, the symposium foregrounds cautious scrutiny of replicating vaccine platforms, frames potential biological and regulatory risks, and calls for careful, evidence‑based assessment before broader deployment.

Ivermectin, known for its use in treating COVID-19, has also shown promise in treating aggressive cancers such as glioblastomas, stage 4 breast and colon cancers, pancreatic cancers, gallbladder cancers, renal cancers, and melanomas. Research suggests that higher doses of Ivermectin can halt the growth and metastasis of these cancer cells, as well as induce apoptosis and autophagy to kill them. It is worth considering Ivermectin as a potential treatment for these aggressive cancers, in addition to its effectiveness against viral outbreaks.

I've been in cancer research for decades and have never seen anything like turbocancer before. It's a phenomenon where cancer develops rapidly in young people within months, leading to late-stage cancer and death. This acceleration is likely caused by genetic injections weakening the immune system, allowing tumors to grow unchecked. This process mirrors what we've observed in animals when their immune systems are compromised. Turbocancer is essentially the unchecked proliferation of cancer cells due to a compromised immune system.

We all carry dormant cancers and tumors to varying degrees. The innate immune system's destruction allows these dormant tumors to become active. Once the immune system is compromised, existing weak cancer cells can proliferate unchecked, similar to antibiotic-resistant bacteria. Each cancer cell is unique, and in a weakened immune environment, those that can survive will thrive rapidly. The immune system's complexity is immense, and its overall functionality is being diminished. Notably, IgG4 levels have surged significantly in those exposed to certain injections, which may suppress the immune response to cancer cells. While the details are complex, the general principles indicate that these changes could hinder the immune system's ability to combat cancer effectively.

COVID-19 vaccines, especially mRNA ones, may promote cancer through impairing DNA repair, inhibiting tumor suppressor systems like p53 and BRCA, and containing DNA impurities. These impurities include fragments from circular DNA used in the manufacturing process, such as SV40, a known proto-oncogene activator. The vaccines could potentially initiate or accelerate cancer growth by weakening natural tumor surveillance systems. This phenomenon is referred to as "turbo cancer."

Humans possess natural killer cells, present for 460 million years, that protect against infection, cancer, and trauma. Current cancer treatments like chemotherapy, radiation, and steroid therapy destroy these cells. A new therapy, approved in 2024, aims to activate these natural killer cells, enabling the body to fight cancer. One injection can unlock these cells so they proliferate and protect you from cancer. Bladder cancer patients have remained disease-free for ten years using this therapy. According to the speaker, the prior presidential administration blocked this therapy along with a COVID treatment and vaccine. This therapy may also treat long COVID, HIV, and sepsis. The speaker plans to discuss this further in a series called "Cancer Decoded."

Chemotherapy was administered to subjects, and researchers found increased chemical markers in their bodies. A new method was developed to track dormant cancer cells in the lungs. Chemo reactivated these dormant cells, triggering metastasis. The same biomarkers were elevated in human blood samples after chemo, suggesting this also occurs in humans. While more study is needed, these findings are concerning because chemotherapy is intended to stop cancer, not reactivate it.

The authors discuss the unusual presence of IgG4 antibodies in mRNA vaccinated individuals, which is not typically seen post-virus infection. IgG4 antibodies are usually associated with parasite infections, allergens, autoimmune diseases, and cancer. The immune system's recognition of repeated antigens can induce IgG4 production, potentially leading to t cell exhaustion and autoimmunity. Scientists are cautious about the implications of IgG4 antibodies and suggest further research comparing outcomes among vaccinated and unvaccinated individuals. This data analysis may reveal any potential clinical impacts over time.

When you fast, your body cleanses itself, using cellular waste for energy through autophagy. There are documented studies showing that fasting can impact cancer by starving it. Cancer thrives on sugar and poor nutrition, consuming a lot of nutrients in the body. By halting eating, you deprive the cancer cells of their primary fuel source, potentially slowing down its progression. Fasting can shift cellular metabolism, and there's evidence that unhealthy metabolic cells can revert to a healthy state, and even be eliminated completely.

Cancer and parasites have been overlooked as a connection, with doctors worldwide sharing videos and research on the topic. A German research project from the 1990s revealed that cancer could be caused by intracellular parasites. Under a microscope, cancer cells resemble parasite egg sacs. Despite this, oncologists have not made the association between cancer and parasites, possibly due to funding concerns.

Sustained stress shuts down the immune system. T cells, which normally protect and kill cancer cells and viruses, are put to sleep. This immunosuppression causes infections to last longer.

Ivermectin, known for its use in treating COVID-19, has also shown promise in treating aggressive cancers like glioblastomas, stage 4 breast and colon cancers, pancreatic cancers, gallbladder cancers, renal cancers, and melanomas. Research suggests that higher doses of Ivermectin can halt the growth and metastasis of these cancer cells, inducing apoptosis and autophagy to kill them. It is worth considering Ivermectin as a potential treatment for these turbo cancers, in addition to its effectiveness against viral outbreaks.

Research has shown that COVID vaccines are contaminated with DNA, including a cancer virus promoter sequence. The DNA can enter the human genome, potentially activating carcinogenic genes and increasing cancer risk. Vaccines suppress immunity, further raising cancer risk. The presence of DNA in vaccines can lead to long-lasting spike production, causing health issues. Vaccines inducing IgG4 antibodies are considered defective. DNA impurities in vaccines can intensify side effects. DNA should not be introduced into the body's cells.

There are concerns that the COVID-19 vaccines may have a potential link to cancer. The spike protein in the vaccines could inhibit tumor suppressor systems in the body. Additionally, the vaccines may impair natural DNA repair mechanisms, increasing the risk of DNA damage. Contamination has also been found in Pfizer vials, which could lead to a direct DNA injection and activation of cancer-related genes. This multi-hit hypothesis suggests that repeated vaccination could promote cancer development. There have been clinical observations of rapid cancer progression and reactivation of cancers in remission after vaccination. However, no agency has confirmed a direct link between vaccines and cancer.

A recent analysis of CDC data shows a concerning trend in cancer deaths among individuals aged 0 to 54. Before 2020, cancer rates were stable, but after the rollout of COVID vaccines in 2021, there has been a statistically significant rise in cancer cases each year. This trend persists despite a decrease in booster vaccinations, suggesting potential long-term effects from the initial vaccines. Observations indicate that some individuals develop aggressive stage 4 cancers months after vaccination, with poor responses to treatment. Research indicates a shift in antibody production, which may lead to the immune system tolerating both the spike protein and cancer cells. This raises concerns about permanent damage from the vaccines that could manifest years later.

There have been reports suggesting a significant increase in cancer rates since the vaccination rollout, with many anecdotal cases emerging globally. The immune system plays a crucial role in identifying and eliminating early cancer cells. However, the vaccination may have impacted immune function, potentially allowing cancers to grow unchecked. The extent of this issue remains unclear, but there are concerns that it could lead to a surge in cancer and other conditions linked to the vaccination program. Notably, some healthcare professionals, like Dr. Ryan Cole in Idaho, have reported increased cancer activity, raising alarms about the lack of thorough studies typically associated with vaccine development, which usually spans 5 to 10 years. This situation is unprecedented and warrants serious attention.

The spike and pseudouridine in the shots are changing receptor patterns on cells, suppressing the immune system's ability to fight off viruses like herpes, HPV, and RSV. Toll-like receptors, which train cells to fight cancer, are also being suppressed. These receptors are like the marines of our immune system, constantly circulating and identifying friend or foe. However, the shots are causing these marines, along with dendritic cells and macrophages, to become inactive, leaving the body defenseless against cancer cells and pathogens. It is unclear when this suppression stops or how to reverse it. While not affecting everyone, the degree to which it is happening is concerning.

After observing unusual relapses in stable melanoma patients who had been undergoing immunotherapy, the speaker noticed a common factor: a recent booster vaccine, with relapses occurring three weeks to three months post-vaccination. This association prompted investigation into the scientific rationale. The speaker recalled a model where a third vaccine dose can cause more inflammation than benefit, detracting from the initial doses. A separate group found that cancer patients receiving a booster experienced T cell exhaustion. The speaker describes T cells as policing cancer cells, and the booster appeared to disrupt this control, depressing T cell response. Additionally, research indicated that after the booster, the immunoglobulin subtype switched to IgG4, which promotes tolerance rather than neutralizing antibodies. This tolerizing effect, desirable in organ transplants, could allow cancer to escape immune detection. The speaker believes these findings warrant a halt to booster vaccinations, citing scientific explanations and observed adverse effects.